Galapagos gains on Phase IIa IPF readout

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said GLPG1690 stabilized lung function in patients with idiopathic pulmonary fibrosis in the Phase IIa FLORA trial. The company plans to "rapidly progress" the selective autotaxin (ENPP2; ATX) inhibitor into a late-stage trial.

Galapagos added €5.20 to €67.83 on Euronext on Thursday, and gained $7.89 (11%) to $81.06 on NASDAQ. The company announced the data after market close on Wednesday...